236 related articles for article (PubMed ID: 35322583)
21. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
[TBL] [Abstract][Full Text] [Related]
22. Initial eGFR Changes with SGLT2 Inhibitor in Patients With Type 2 Diabetes and Associations With the Risk of Abnormal Serum Potassium Level.
Kao YW; Chao TF; Chen SW; Cheng YW; Chan YH; Chu PH
J Am Heart Assoc; 2024 May; 13(9):e033236. PubMed ID: 38686902
[TBL] [Abstract][Full Text] [Related]
23. Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents.
Carretero Gómez J; Ena J; Seguí Ripoll JM; Carrasco-Sanchez FJ; Gómez Huelgas R; Mateos Polo L; Varela Aguilar JM; Suárez Tembra JM; Arévalo-Lorido JC;
Int J Clin Pract; 2020 Oct; 74(10):e13586. PubMed ID: 32533906
[TBL] [Abstract][Full Text] [Related]
24. Retrospective Analysis of the Renoprotective Effects of Long-Term Use of Six Types of Sodium-Glucose Cotransporter 2 Inhibitors in Japanese Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Kobayashi K; Toyoda M; Hatori N; Saito N; Kanaoka T; Sakai H; Furuki T; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Yamamoto H; Machimura H; Chin K; Hishiki T; Takihata M; Aoyama K; Umezawa S; Minamisawa K; Aoyama T; Hamada Y; Suzuki Y; Hayashi M; Hatori Y; Sato K; Miyakawa M; Tamura K; Kanamori A
Diabetes Technol Ther; 2021 Feb; 23(2):110-119. PubMed ID: 32721227
[No Abstract] [Full Text] [Related]
25. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.
Jeong SJ; Lee SE; Shin DH; Park IB; Lee HS; Kim KA
BMC Nephrol; 2021 May; 22(1):177. PubMed ID: 33990175
[TBL] [Abstract][Full Text] [Related]
26. Abrupt Decline in Estimated Glomerular Filtration Rate after Initiating Sodium-Glucose Cotransporter 2 Inhibitors Predicts Clinical Outcomes: A Systematic Review and Meta-Analysis.
Chuang MH; Tang YS; Chen JY; Pan HC; Liao HW; Chu WK; Cheng CY; Wu VC; Heung M
Diabetes Metab J; 2024 Mar; 48(2):242-252. PubMed ID: 38273790
[TBL] [Abstract][Full Text] [Related]
27. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis.
Lui DTW; Au ICH; Tang EHM; Cheung CL; Lee CH; Woo YC; Wu T; Tan KCB; Wong CKH
EClinicalMedicine; 2022 Aug; 50():101510. PubMed ID: 35784442
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
29. Effect of Sodium Glucose Cotransporter 2 Inhibitors on Renal Function in Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Japan.
Yano K; Seko Y; Takahashi A; Okishio S; Kataoka S; Takemura M; Okuda K; Mizuno N; Taketani H; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Okanoue T; Itoh Y
Diagnostics (Basel); 2020 Feb; 10(2):. PubMed ID: 32041289
[TBL] [Abstract][Full Text] [Related]
30. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists.
Kobayashi K; Toyoda M; Hatori N; Sakai H; Furuki T; Chin K; Kimura M; Saito N; Kanaoka T; Aoyama T; Umezono T; Ito S; Suzuki D; Takeda H; Minagawa F; Degawa H; Machimura H; Hishiki T; Umezawa S; Shimura H; Nakajima S; Yamamoto H; Sato K; Miyakawa M; Terauchi Y; Tamura K; Kanamori A
Diabetes Res Clin Pract; 2022 Mar; 185():109231. PubMed ID: 35131376
[TBL] [Abstract][Full Text] [Related]
31. Independent risk factors of rapid glomerular filtration rate decline in patients with type 2 diabetes with preserved kidney function and normoalbuminuria: A multicenter cohort study.
Hirano D; Unoki-Kubota H; Imasawa T; Yamamoto-Honda R; Kajio H; Yamashita S; Fukazawa Y; Seki N; Noda M; Kaburagi Y
J Diabetes Investig; 2023 Jul; 14(7):874-882. PubMed ID: 37026171
[TBL] [Abstract][Full Text] [Related]
32. The Urinary Glucose Excretion by Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Different Levels of Renal Function: A Systematic Review and Meta-Analysis.
Hu S; Lin C; Cai X; Zhu X; Lv F; Nie L; Ji L
Front Endocrinol (Lausanne); 2021; 12():814074. PubMed ID: 35154011
[TBL] [Abstract][Full Text] [Related]
33. Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation.
Lemke A; Brokmeier HM; Leung SB; Mara KC; Mour GK; Wadei HM; Hill JM; Stegall M; Kudva YC; Shah P; Kukla A
Clin Transplant; 2022 Aug; 36(8):e14718. PubMed ID: 35593882
[TBL] [Abstract][Full Text] [Related]
34. Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study.
Lin FJ; Wang CC; Hsu CN; Yang CY; Wang CY; Ou HT
Cardiovasc Diabetol; 2021 Oct; 20(1):203. PubMed ID: 34620182
[TBL] [Abstract][Full Text] [Related]
35. Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study.
Ishibashi F; Kosaka A; Tavakoli M
Front Endocrinol (Lausanne); 2022; 13():864332. PubMed ID: 35784562
[TBL] [Abstract][Full Text] [Related]
36. Baseline eGFR, albuminuria and renal outcomes in patients with SGLT2 inhibitor treatment: an updated meta-analysis.
Ma Y; Lin C; Cai X; Hu S; Zhu X; Lv F; Yang W; Ji L
Acta Diabetol; 2023 Mar; 60(3):435-445. PubMed ID: 36609865
[TBL] [Abstract][Full Text] [Related]
37. Correlation between albuminuria and interstitial injury marker reductions associated with SGLT2 inhibitor treatment in diabetic patients with renal dysfunction.
Sato S; Takayanagi K; Shimizu T; Kanozawa K; Iwashita T; Hasegawa H
Eur J Med Res; 2022 Aug; 27(1):140. PubMed ID: 35933386
[TBL] [Abstract][Full Text] [Related]
38. Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases.
Iijima H; Gouda M; Hida H; Mori-Anai K; Takahashi A; Minai R; Ninomiya H; Saito Y; Miyawaki A; Wada J
Diabetes Obes Metab; 2024 May; 26(5):1615-1623. PubMed ID: 38413384
[TBL] [Abstract][Full Text] [Related]
39. Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study).
Kato S; Kuwatsuka Y; Ando M; Tatematsu Y; Nishibori N; Maruyama S
BMC Nephrol; 2023 Aug; 24(1):228. PubMed ID: 37537531
[TBL] [Abstract][Full Text] [Related]
40. Comparative Effectiveness of the Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events.
Xie Y; Bowe B; Gibson AK; McGill JB; Yan Y; Maddukuri G; Al-Aly Z
Diabetes Care; 2020 Nov; 43(11):2785-2795. PubMed ID: 32912850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
